Billiontoone (NASDAQ:BLLN) Insider Sells $3,873,906.96 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Thomas Lynch sold 35,112 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $110.33, for a total transaction of $3,873,906.96. Following the completion of the transaction, the insider owned 700 shares in the company, valued at $77,231. This represents a 98.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Trading Down 1.4%

NASDAQ:BLLN opened at $114.42 on Thursday. The firm has a market capitalization of $5.40 billion and a P/E ratio of 163.46. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. The company has a fifty day moving average of $108.94 and a 200 day moving average of $97.79. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $150.44.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The business had revenue of $109.45 million for the quarter. On average, research analysts predict that Billiontoone, Inc. will post 0.83 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on BLLN. Zacks Research lowered Billiontoone from a “hold” rating to a “strong sell” rating in a research report on Monday, August 31st. Weiss Ratings reiterated a “sell (d+)” rating on shares of Billiontoone in a research report on Friday, September 18th. Wall Street Zen cut Billiontoone from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. JPMorgan Chase & Co. decreased their target price on Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a report on Thursday, August 6th. Finally, Guggenheim assumed coverage on Billiontoone in a research note on Monday, June 29th. They issued a “buy” rating and a $125.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $125.88.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Integrated Wealth Concepts LLC purchased a new position in shares of Billiontoone in the 2nd quarter valued at approximately $29,000. MCF Advisors LLC grew its stake in Billiontoone by 330.8% in the second quarter. MCF Advisors LLC now owns 448 shares of the company’s stock worth $54,000 after purchasing an additional 344 shares during the period. Thrive Wealth Management LLC purchased a new stake in Billiontoone in the second quarter worth $240,000. Caitong International Asset Management Co. Ltd bought a new position in Billiontoone in the fourth quarter worth $230,000. Finally, Jasper Ridge Partners L.P. purchased a new position in Billiontoone during the second quarter valued at $615,000.

About Billiontoone

BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company’s technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.

The company’s primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.